Pemetrexed Plus Gemcitabine as Front-Line Chemotherapy for Patients With Malignant Pleural or Peritoneal Mesothelioma
Status:
Completed
Trial end date:
2006-09-01
Target enrollment:
Participant gender:
Summary
The purposes of this study are to determine:
1. The safety of Pemetrexed plus Gemcitabine and any side effects that might be associated
with the combination of these two drugs.
2. Whether Pemetrexed plus Gemcitabine can help patients with mesothelioma live longer.
3. Whether Pemetrexed plus Gemcitabine can make the tumor smaller or disappear, and for how
long.
4. To see if patients feel better while taking Pemetrexed plus Gemcitabine.